Overexpression of RKIP inhibits cell invasion in glioma cell lines through upregulation of miR-98

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Chen, Zigui ^a   Cheng, Quan ^a   Ma, Zhiming ^a   Xi, Haipeng ^a   Peng, Renjun ^a   Jiang, Bing ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH MOBILITY GROUP A2 PROTEIN; MICRORNA; MIRN98 MICRORNA, HUMAN; PEBP1 PROTEIN, HUMAN; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN;

ARTICLE; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENETICS; GLIOMA; HUMAN; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR INVASION;

CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HMGA2 PROTEIN; HUMANS; MICRORNAS; NEOPLASM INVASIVENESS; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; SIGNAL TRANSDUCTION;

EID: 84893774245     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/695179     Document Type: Article

References (38)

1. Huse J. T., Holland E. C., Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nature Reviews Cancer 2010 10 5 319 331 2-s2.0-77951599543 10.1038/nrc2818
2. Holmen S. L., Williams B. O., Essential role for Ras signaling in glioblastoma maintenance. Cancer Research 2005 65 18 8250 (Pubitemid 41330589)
3. Jeuken J., van de Broecke C., Gijsen S., Boots-Sprenger S., Wesseling P., RAS/RAF pathway activation in gliomas: the result of copy number gains rather than activating mutations. Acta Neuropathologica 2007 114 2 121 133 2-s2.0-34547100321 10.1007/s00401-007-0239-0 (Pubitemid 47103523)
4. Goldberg L., Kloog Y., A Ras inhibitor tilts the balance between Rac and Rho and blocks phosphatidylinositol 3-kinase-dependent glioblastoma cell migration. Cancer Research 2006 66 24 11709 11717 2-s2.0-33846205171 10.1158/0008-5472.CAN-06-1878 (Pubitemid 46094183)
5. Hjelmeland A. B., Lattimore K. P., Fee B. E., Shi Q., Wickman S., Keir S. T., Hjelmeland M. D., Batt D., Bigner D. D., Friedman H. S., Rich J. N., The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion. Molecular Cancer Therapeutics 2007 6 9 2449 2457 2-s2.0-34748821802 10.1158/1535-7163.MCT- 07-0155 (Pubitemid 47480410)
6. Zeng L., Imamoto A., Rosner M. R., Raf kinase inhibitory protein (RKIP): a physiological regulator and future therapeutic target. Expert Opinion on Therapeutic Targets 2008 12 10 1275 1287 2-s2.0-54349109317 10.1517/14728222.12. 10.1275
7. Granovsky A. E., Rosner M. R., Raf kinase inhibitory protein: a signal transduction modulator and metastasis suppressor. Cell Research 2008 18 4 452 457 2-s2.0-41849102400 10.1038/cr.2008.43 (Pubitemid 351498852)
8. Klysik J., Theroux S. J., Sedivy J. M., Moffit J. S., Boekelheide K., Signaling crossroads: the function of Raf kinase inhibitory protein in cancer, the central nervous system and reproduction. Cellular Signalling 2008 20 1 1 9 2-s2.0-36248980460 10.1016/j.cellsig.2007.07.003 (Pubitemid 350138364)
9. Yun J., Frankenberger C. A., Kuo W.-L., Boelens M. C., Eves E. M., Cheng N., Liang H., Li W.-H., Ishwaran H., Minn A. J., Rosner M. R., Signalling pathway for RKIP and Let-7 regulates and predicts metastatic breast cancer. EMBO Journal 2011 30 21 4500 4514 2-s2.0-80455174648 10.1038/emboj.2011.312
10. Dangi-Garimella S., Yun J., Eves E. M., Newman M., Erkeland S. J., Hammond S. M., Minn A. J., Rosner M. R., Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7. EMBO Journal 2009 28 4 347 358 2-s2.0-60549104367 10.1038/emboj.2008.294
11. Hebert C., Norris K., Scheper M. A., Nikitakis N., Sauk J. J., High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Molecular Cancer 2007 6 5 16 2-s2.0-33846941188 10.1186/1476-4598-6-5
12. Motoyama K., Inoue H., Nakamura Y., Uetake H., Sugihara K., Mori M., Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 MicroRNA family. Clinical Cancer Research 2008 14 8 2334 2340 2-s2.0-42249103794 10.1158/1078-0432.CCR-07-4667 (Pubitemid 351551065)
13. Hristov A. C., Cope L., Reyes M. D., Singh M., Iacobuzio-Donahue C., Maitra A., Resar L. M. S., HMGA2 protein expression correlates with lymph node metastasis and increased tumor grade in pancreatic ductal adenocarcinoma. Modern Pathology 2009 22 1 43 49 2-s2.0-58149148165 10.1038/modpathol.2008.140
14. Meyer B., Loeschke S., Schultze A., Weigel T., Sandkamp M., Goldmann T., Vollmer E., Bullerdiek J., HMGA2 overexpression in non-small cell lung cancer. Molecular Carcinogenesis 2007 46 7 503 511 2-s2.0-34447532061 10.1002/mc.20235 (Pubitemid 47068069)
15. Chiappetta G., Ferraro A., Vuttariello E., Monaco M., Galdiero F., De Simone V., Califano D., Pallante P., Botti G., Pezzullo L., Pierantoni G. M., Santoro M., Fusco A., HMGA2 mRNA expression correlates with the malignant phenotype in human thyroid neoplasias. European Journal of Cancer 2008 44 7 1015 1021 2-s2.0-43049117843 10.1016/j.ejca.2008.02.039
16. Miyazawa J., Mitoro A., Kawashiri S., Chada K. K., Imai K., Expression of mesenchyme-specific gene HMGA2 in squamous cell carcinomas of the oral cavity. Cancer Research 2004 64 6 2024 2029 2-s2.0-1542720383 10.1158/0008-5472.CAN-03- 1855 (Pubitemid 38339449)
17. Malek A., Bakhidze E., Noske A., Sers C., Aigner A., Schäfer R., Tchernitsa O., HMGA2 gene is a promising target for ovarian cancer silencing therapy. International Journal of Cancer 2008 123 2 348 356 2-s2.0-44949237000 10.1002/ijc.23491 (Pubitemid 351842019)
18. Claes A., Idema A. J., Wesseling P., Diffuse glioma growth: a guerilla war. Acta Neuropathologica 2007 114 5 443 458 2-s2.0-34948892058 10.1007/s00401-007-0293-7 (Pubitemid 47521501)
19. Louis D. N., Ohgaki H., Wiestler O. D., Cavenee W. K., Burger P. C., Jouvet A., Scheithauer B. W., Kleihues P., The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathologica 2007 114 2 97 109 2-s2.0-34547122001 10.1007/s00401-007-0243-4 (Pubitemid 47103521)
20. Wen P. Y., Kesari S., Malignant gliomas in adults. The New England Journal of Medicine 2008 359 5 492 507 2-s2.0-48249125791 10.1056/NEJMra0708126
21. Hoelzinger D. B., Demuth T., Berens M. E., Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment. Journal of the National Cancer Institute 2007 99 21 1583 1593 2-s2.0-36048994736 10.1093/jnci/djm187 (Pubitemid 351767231)
22. Keller E. T., Fu Z., Brennan M., The role of Raf kinase inhibitor protein (RKIP) in health and disease. Biochemical Pharmacology 2004 68 6 1049 1053 2-s2.0-4143071652 10.1016/j.bcp.2004.04.024 (Pubitemid 39094269)
23. Keller E. T., Metastasis suppressor genes: a role for raf kinase inhibitor protein (RKIP). Anti-Cancer Drugs 2004 15 7 663 669 2-s2.0-4143151672 10.1097/01.cad.0000136877.89057.b9 (Pubitemid 39099915)
24. Keller E. T., Fu Z., Brennan M., The biology of a prostate cancer metastasis suppressor protein: raf kinase inhibitor protein. Journal of Cellular Biochemistry 2005 94 2 273 278 2-s2.0-18444400873 10.1002/jcb.20169 (Pubitemid 41420306)
25. Kim H.-S., Kim G. Y., Lim S.-J., Kim Y. W., Loss of Raf-1 kinase inhibitory protein in pancreatic ductal adenocarcinoma. Pathology 2010 42 7 655 660 2-s2.0-78649265598 10.3109/00313025.2010.522172
26. Xu Y.-F., Yi Y., Qiu S.-J., Gao Q., Li Y.-W., Dai C.-X., Cai M.-Y., Ju M.-J., Zhou J., Zhang B.-H., Fan J., PEBP1 downregulation is associated to poor prognosis in HCC related to hepatitis B infection. Journal of Hepatology 2010 53 5 872 879 2-s2.0-77957359351 10.1016/j.jhep.2010.05.019
27. Chatterjee D., Sabo E., RosemarieTavares R., Resnick M. B., Inverse association between raf kinase inhibitory protein and signal transducers and activators of transcription 3 expression in gastric adenocarcinoma patients: implications for clinical outcome. Clinical Cancer Research 2008 14 10 2994 3001 2-s2.0-49649114120 10.1158/1078-0432.CCR-07-4496
28. Martinho O., Gouveia A., Silva P., Pimenta A., Reis R. M., Lopes J. M., Loss of RKIP expression is associated with poor survival in GISTs. Virchows Archiv 2009 455 3 277 284 2-s2.0-70349285960 10.1007/s00428-009-0821-z
29. Martinho O., Granja S., Jaraquemada T., Caeiro C., Miranda- Gonçalves V., Honavar M., Costa P., Damasceno M., Rosner M. R., Lopes J. M., Reis R. M., Downregulation of RKIP is associated with poor outcome and malignant progression in gliomas. PLoS ONE 2012 7 1 2-s2.0-84856088642 10.1371/journal.pone.0030769 e30769
30. Maresch J., Birner P., Zakharinov M., Toumangelova-Uzeir K., Natchev S., Guentchev M., Additive effect on survival of raf kinase inhibitor protein and signal transducer and activator of transcription 3 in high-grade glioma. Cancer 2011 117 11 2499 2504 2-s2.0-79958696639 10.1002/cncr.25799
31. Roush S., Slack F. J., The let-7 family of microRNAs. Trends in Cell Biology 2008 18 10 505 516 2-s2.0-52949091534 10.1016/j.tcb.2008.07.007
32. Yu J., Wang F., Yang G.-H., Wang F.-L., Ma Y.-N., Du Z.-W., Zhang J.-W., Human microRNA clusters: genomic organization and expression profile in leukemia cell lines. Biochemical and Biophysical Research Communications 2006 349 1 59 68 2-s2.0-33748286897 10.1016/j.bbrc.2006.07.207 (Pubitemid 44331762)
33. Hebert C., Norris K., Scheper M. A., Nikitakis N., Sauk J. J., High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Molecular Cancer 2007 6, article 5 2-s2.0-33846941188 10.1186/1476-4598-6-5
34. Alajez N. M., Shi W., Hui A. B. Y., Bruce J., Lenarduzzi M., Ito E., Yue S., O'Sullivan B., Liu F.-F., Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98. Cell Death and Disease 2010 1 10, article e85 2-s2.0-79957552560 10.1038/cddis.2010.64
35. Wu W., Sun M., Zou G.-M., Chen J., MicroRNA and cancer: current status and prospective. International Journal of Cancer 2007 120 5 953 960 2-s2.0-33846846397 10.1002/ijc.22454 (Pubitemid 46214293)
36. Dangi-Garimella S., Yun J., Eves E. M., Newman M., Erkeland S. J., Hammond S. M., Minn A. J., Rosner M. R., Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7. EMBO Journal 2009 28 4 347 358 2-s2.0-60549104367 10.1038/emboj.2008.294
37. Schuierer M. M., Bataille F., Hagan S., Kolch W., Bosserhoff A.-K., Reduction in Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines. Cancer Research 2004 64 15 5186 5192 2-s2.0-3442883359 10.1158/0008-5472.CAN-03-3861 (Pubitemid 39006537)
38. Fu Z., Smith P. C., Zhang L., Rubin M. A., Dunn R. L., Yao Z., Keller E. T., Effects of Raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. Journal of the National Cancer Institute 2003 95 12 878 889 2-s2.0-0038275924 (Pubitemid 36833879)